A 12 Week Multicenter, Open-Label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma.

Trial Profile

A 12 Week Multicenter, Open-Label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Corticosteroids; Montelukast
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms Pediatric-ACTION3
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top